SUMMARY
Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of COVID19 in health personnel exposed to patients infected by SARS-COV-2.
Methods Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVD19 patients. Main outcome was time to symptomatic SARS-CoV2 infection.
Results 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9,2%) subjects in the placebo group developed COVID-19. (Log Rank test p = 0.09). No severe COVID19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19.
CONCLUSION Although the number of symptomatic infections in health personnel was lower in the HCQ group, the difference was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04318015
Funding Statement
Support for the trial was received from the Instituto Nacional de Enfermedades Respiratorias (INER), from CONACYT (national council of science and technology) and by SANOFI-AVENTIS through an investigator-sponsored trial. Neither the INER, CONACYT or SANOFI AVENTIS had role in the des ign of the study, collection of data, analysis, results interpretation, the writing of the final report and the decision to submit the article to publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics in Research Committee and the Research Committee of the Instituto Nacional de Enfermedades Respiratorias (National Institute of Respiratory Diseases) in Mexico, with number C14-20.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
On behalf of the RESEARCH GROUP ON HYDROXYCHLOROQUINE FOR COVID-19 also formed by Dr. Cristobal Guadarrama, Dr. Carmen Margarita Hernández Cárdenas, Dr. Luis Felipe Jurado Camacho Dr. Sebastián Rodríguez Llamazares, Dra. Alejandra Ramírez Venegas
Data Availability
We are making our dataset available in the link below, under Creative Commons license. The protocol is the one registered at clinicaltrials.gov.
https://figshare.com/s/04ea689e248e1a52fe2c
https://clinicaltrials.gov/ct2/show/study/NCT04318015?term=phydra&draw=2&rank=1